Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult cancers with…
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma…
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…
The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials…
- AB126 is an unmodified exosome derived from neural stem cells with the innate ability to cross the blood-brain-barrier and…
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a…
MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or…
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to…
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical…
BOSTON, MA / ACCESSWIRE / August 15, 2023 / The VA Boston Healthcare System has implemented the Palarum® PUP® SmartSock…